Recruiting
Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women
This randomized trial aims to test the effects of co-created breast cancer counter marketing intervention messages for reducing alcohol consumption and impacting awareness and beliefs about the breast cancer risks from alcohol consumption in young adult women.
ClinicalTrials.gov IDNCT07320664
PhaseNA
Enrollment500
SponsorOhio State University Comprehensive Cancer Center
Age18 Years
SexFEMALE
Conditions studied
Behavior, Risk
About this study
This randomized trial aims to test the effects of co-created breast cancer counter marketing intervention messages for reducing alcohol consumption and impacting awareness and beliefs about the breast cancer risks from alcohol consumption in young adult women.
Interventions
- Behavioral: Alcohol and Breast Cancer Risk Messages — Participants will be randomized in a 1:1 ratio to the intervention or control arm. In the intervention arm, participants will receive the co-created intervention content. The investigators co-created the intervention content, including visuals and text, through focus groups with young adult women and refined the draft content based on additional feedback from focus groups, thereby ascertaining the views of young adult women. The intervention content aligns with a conceptual framework and includes messaging with the following themes: 1) Risks of breast cancer from alcohol consumption; 2) Efficacy content promoting behavior change; 3) Relevance to young adult women; 4) Mechanisms through which alcohol consumption increases breast cancer risk; 5) Exposing the alcohol industry's deceptive marketing practices; 6) Comparisons to other behavioral risk factors for cancer.
- Behavioral: Skin Cancer Risk Messages — Participants in the control arm will receive text only content about skin cancer risk and prevention. This is based on intervention trials in other cancer prevention areas (e.g., tobacco) where the investigators used this type of control, provides a contact-matched comparison relative to the intervention arm, and ensures consistency of the protocol (e.g., timing of completion and content of measures to be completed) across the trial arms.
Primary outcomes
- Alcohol Consumption (12 weeks post intervention)
- Daily Alcohol Consumption (12 weeks post intervention)
- Intentions to Reduce Alcohol Consumption (12 weeks post intervention)
- Alcohol and Breast Cancer Risk Beliefs (12 weeks post intervention)
- Alcohol and Breast Cancer Efficacy Beliefs (12 weeks post intervention)
- Awareness of the Risks of Breast Cancer from Drinking Alcohol (12 weeks post intervention)
- Transdermal Alcohol Concentration (12 weeks post intervention)
Eligibility information
Inclusion Criteria:
* Assigned female at birth.
* Age 18-25 at enrollment.
* Report drinking alcohol at least once in the past 30 days.
* Not pregnant or intending to become pregnant by self-report.
* Reside in Ohio, Michigan, Illinois, Wisconsin, or New Jersey.
* Willing to complete procedures.
* Able to complete procedures a, b, or c:
1. Can read, write, and converse in English.
2. Has a personal mobile smartphone with texting capabilities to receive text messages that may contain text and images.
3. For the subsample who will wear the BACTrack sensor, they must have an iPhone. At the time of this protocol, the BACTrack skyn app is only compatible with iPhones. If this expands to Android phones over the course of the study, Android phones will be eligible.
Exclusion Criteria:
* Assigned male at birth
* Ages \<18 or \>25 at enrollment
* Do not report drinking alcohol at least once in the past 30 days
* Pregnant or intending to become pregnant by self-report.
* Do not reside in Ohio, Michigan, Illinois, Wisconsin, or New Jersey.
* Not willing to complete procedures.
* Unable to complete procedures.
Study locations
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.